Alkermes PLC Company Profile (NASDAQ:ALKS)

About Alkermes PLC

Alkermes PLC logoAlkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. Its products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. Its product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ALKS
  • CUSIP: G0176710
Key Metrics:
  • Previous Close: $44.17
  • 50 Day Moving Average: $47.71
  • 200 Day Moving Average: $40.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -445.00
  • P/E Growth: 7.40
  • Market Cap: $6.74B
  • Outstanding Shares: 151,556,000
  • Beta: 1.91
Additional Links:
Companies Related to Alkermes PLC:

Analyst Ratings

Consensus Ratings for Alkermes PLC (NASDAQ:ALKS) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $53.11 (19.35% upside)

Analysts' Ratings History for Alkermes PLC (NASDAQ:ALKS)
Show:
DateFirmActionRatingPrice TargetDetails
7/29/2016JPMorgan Chase & Co.Reiterated RatingHold$51.00View Rating Details
7/29/2016Jefferies GroupBoost Price TargetBuy$54.00 -> $62.00View Rating Details
7/29/2016Barclays PLCBoost Price TargetOverweight$65.00 -> $66.00View Rating Details
6/28/2016Leerink SwannReiterated RatingOutperform$58.00 -> $54.00View Rating Details
6/2/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details
5/26/2016Evercore ISIInitiated CoverageBuy$59.00View Rating Details
5/5/2016Cowen and CompanyInitiated CoverageMarket PerformView Rating Details
4/30/2016Morgan StanleyReiterated RatingSellView Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$57.00 -> $35.00View Rating Details
2/8/2016Citigroup Inc.Lower Price TargetNeutral$36.00View Rating Details
1/21/2016GuggenheimReiterated RatingHoldView Rating Details
2/25/2015Bank of America Corp.Set Price TargetSell$45.00View Rating Details
1/8/2015MizuhoBoost Price TargetBuy$72.00 -> $81.00View Rating Details
(Data available from 8/27/2014 forward)

Earnings

Earnings History for Alkermes PLC (NASDAQ:ALKS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016        
7/28/2016Q216($0.10)($0.01)$174.15 million$195.20 millionViewListenView Earnings Details
4/28/2016Q116($0.20)($0.16)$153.64 million$156.80 millionViewListenView Earnings Details
2/25/2016Q415($0.18)($0.15)$161.24 million$163.10 millionViewListenView Earnings Details
10/29/2015Q315($0.21)($0.18)$151.77 million$152.70 millionViewListenView Earnings Details
7/30/2015Q215($0.10)($0.09)$142.80 million$151.40 millionViewListenView Earnings Details
4/30/2015Q115($0.03)$0.06$146.60 million$161.20 millionViewListenView Earnings Details
2/24/2015Q414$0.04$0.11$161.70 million$175.20 millionViewListenView Earnings Details
10/29/2014Q314$0.02$0.03$155.53 million$160.00 millionViewListenView Earnings Details
7/31/2014Q314$0.14$0.11$146.91 million$153.40 millionViewListenView Earnings Details
4/30/2014Q1$0.10$0.11$135.79 million$130.21 millionViewListenView Earnings Details
2/27/2014Q114$0.20$0.27$142.93 million$154.50 millionViewListenView Earnings Details
10/31/2013$0.22$0.22$137.35 million$139.80 millionViewListenView Earnings Details
7/25/2013Q1 2014$0.22$0.30$131.50 million$138.60 millionViewListenView Earnings Details
5/23/2013Q4 2013$0.17$0.40$128.01 million$163.40 millionViewListenView Earnings Details
1/31/2013Q3 2013$0.23$0.34$130.81 million$135.90 millionViewListenView Earnings Details
11/1/2012Q213$0.11$0.17$121.62 million$124.00 millionViewN/AView Earnings Details
7/26/2012$0.16$0.39ViewN/AView Earnings Details
5/17/2012($0.16)($0.14)ViewN/AView Earnings Details
2/2/2012($0.21)($0.11)ViewN/AView Earnings Details
11/3/2011($0.10)($0.22)ViewN/AView Earnings Details
8/1/2011($0.11)$0.02ViewN/AView Earnings Details
5/18/2011($0.14)($0.14)ViewN/AView Earnings Details
2/3/2011($0.15)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alkermes PLC (NASDAQ:ALKS)
Current Year EPS Consensus Estimate: $-0.86 EPS
Next Year EPS Consensus Estimate: $-0.1 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alkermes PLC (NASDAQ:ALKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Alkermes PLC (NASDAQ:ALKS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/4/2016Paul J MitchellDirectorSell2,000$49.48$98,960.00View SEC Filing  
7/27/2016Elliot EhrichCMOSell35,199$51.95$1,828,588.05View SEC Filing  
7/5/2016Paul J MitchellDirectorSell2,000$45.81$91,620.00View SEC Filing  
6/6/2016Paul J MitchellDirectorSell2,000$44.98$89,960.00View SEC Filing  
5/4/2016Paul J MitchellDirectorSell2,000$38.60$77,200.00View SEC Filing  
4/20/2016Michael J LandineSVPSell16,875$41.09$693,393.75View SEC Filing  
4/19/2016Richard F PopsCEOSell18,750$40.15$752,812.50View SEC Filing  
4/18/2016Iain Michael BrownCAOSell5,368$39.27$210,801.36View SEC Filing  
4/13/2016Elliot EhrichCMOSell11,698$37.66$440,546.68View SEC Filing  
4/12/2016Richard F PopsCEOSell25,000$37.79$944,750.00View SEC Filing  
4/4/2016Paul J MitchellDirectorSell2,000$35.65$71,300.00View SEC Filing  
3/22/2016Richard F PopsCEOSell25,000$31.77$794,250.00View SEC Filing  
3/15/2016Richard F PopsCEOSell25,000$31.40$785,000.00View SEC Filing  
3/4/2016Paul J MitchellDirectorSell2,000$32.80$65,600.00View SEC Filing  
3/3/2016David W AnsticeDirectorBuy5,000$32.87$164,350.00View SEC Filing  
2/4/2016Paul J. MitchellDirectorSell2,000$32.81$65,620.00View SEC Filing  
1/4/2016Robert A BreyerDirectorSell2,000$77.33$154,660.00View SEC Filing  
12/28/2015Mark StejbachinsiderSell10,000$80.24$802,400.00View SEC Filing  
12/23/2015Shane CookeinsiderSell18,000$77.23$1,390,140.00View SEC Filing  
12/7/2015Michael J. LandineSVPSell3,750$73.02$273,825.00View SEC Filing  
12/7/2015Richard F. PopsCEOSell37,500$72.06$2,702,250.00View SEC Filing  
12/1/2015Mark StejbachinsiderSell18,000$72.18$1,299,240.00View SEC Filing  
12/1/2015Michael J. LandineSVPSell10,000$72.18$721,800.00View SEC Filing  
12/1/2015Richard F. PopsCEOSell50,000$72.29$3,614,500.00View SEC Filing  
12/1/2015Robert A BreyerDirectorSell2,000$73.46$146,920.00View SEC Filing  
11/23/2015Shane CookeinsiderSell18,000$72.62$1,307,160.00View SEC Filing  
11/2/2015Mark StejbachinsiderSell18,000$72.06$1,297,080.00View SEC Filing  
11/2/2015Robert A BreyerDirectorSell2,000$71.80$143,600.00View SEC Filing  
10/29/2015Iain Michael BrownCAOSell10,822$69.99$757,431.78View SEC Filing  
10/23/2015Shane CookeinsiderSell18,000$62.03$1,116,540.00View SEC Filing  
10/13/2015James M. FratesCFOSell20,000$59.78$1,195,600.00View SEC Filing  
10/2/2015Robert A. BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
9/23/2015Shane CookeinsiderSell18,000$67.09$1,207,620.00View SEC Filing  
9/17/2015Michael J. LandineSVPSell10,000$71.20$712,000.00View SEC Filing  
9/17/2015Richard F. PopsCEOSell50,000$71.27$3,563,500.00View SEC Filing  
9/15/2015James M. FratesCFOSell20,000$71.10$1,422,000.00View SEC Filing  
9/10/2015Michael J. LandineSVPSell10,000$67.61$676,100.00View SEC Filing  
9/10/2015Richard F. PopsCEOSell50,000$67.57$3,378,500.00View SEC Filing  
9/1/2015Robert A BreyerDirectorSell2,000$61.43$122,860.00View SEC Filing  
8/24/2015Shane CookeinsiderSell18,000$57.65$1,037,700.00View SEC Filing  
7/23/2015Shane CookeInsiderSell18,000$69.79$1,256,220.00View SEC Filing  
7/20/2015Gordon G PughCOOSell18,750$70.10$1,314,375.00View SEC Filing  
7/14/2015James M FratesCFOSell20,000$65.79$1,315,800.00View SEC Filing  
7/1/2015Gordon G PughCOOSell13,750$65.13$895,537.50View SEC Filing  
7/1/2015Robert A BreyerDirectorSell2,000$64.90$129,800.00View SEC Filing  
6/23/2015Shane CookeInsiderSell18,000$66.84$1,203,120.00View SEC Filing  
6/17/2015Paul J MitchellDirectorSell15,500$65.10$1,009,050.00View SEC Filing  
6/16/2015Gordon G PughCOOSell32,977$63.11$2,081,178.47View SEC Filing  
6/16/2015James M FratesCFOSell10,000$58.63$586,300.00View SEC Filing  
6/1/2015Paul J MitchellDirectorSell1,500$60.78$91,170.00View SEC Filing  
6/1/2015Rebecca PetersonSVPSell21,983$60.05$1,320,079.15View SEC Filing  
5/26/2015Rebecca PetersonSVPSell1,322$60.49$79,967.78View SEC Filing  
5/26/2015Shane CookeInsiderSell18,000$60.31$1,085,580.00View SEC Filing  
5/22/2015Rebecca PetersonSVPSell28,558$61.71$1,762,314.18View SEC Filing  
5/12/2015James M FratesCFOSell10,000$59.34$593,400.00View SEC Filing  
5/4/2015Robert A BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
5/1/2015Paul J MitchellDirectorSell1,500$55.79$83,685.00View SEC Filing  
4/23/2015Shane CookeInsiderSell18,000$62.55$1,125,900.00View SEC Filing  
4/21/2015Elliot EhrichCMOSell25,000$62.39$1,559,750.00View SEC Filing  
4/15/2015Gordon G PughCOOSell13,750$63.21$869,137.50View SEC Filing  
4/15/2015James M FratesCFOSell10,000$62.42$624,200.00View SEC Filing  
4/15/2015Paul J MitchellDirectorSell1,500$62.71$94,065.00View SEC Filing  
4/1/2015Robert A BreyerDirectorSell5,000$61.22$306,100.00View SEC Filing  
3/23/2015Shane CookeInsiderSell18,000$65.33$1,175,940.00View SEC Filing  
3/16/2015Elliot EhrichCMOSell18,000$66.81$1,202,580.00View SEC Filing  
3/10/2015James M FratesCFOSell10,000$66.25$662,500.00View SEC Filing  
3/5/2015Rebecca PetersonSVPSell17,737$71.37$1,265,889.69View SEC Filing  
3/2/2015Gordon G PughCOOSell15,000$71.39$1,070,850.00View SEC Filing  
3/2/2015Robert A BreyerDirectorSell5,000$70.86$354,300.00View SEC Filing  
2/23/2015Shane CookeInsiderSell18,000$74.29$1,337,220.00View SEC Filing  
2/17/2015Elliot EhrichCMOSell18,000$70.87$1,275,660.00View SEC Filing  
2/3/2015James M FratesCFOSell10,000$70.83$708,300.00View SEC Filing  
2/2/2015Gordon G PughCOOSell15,000$72.01$1,080,150.00View SEC Filing  
2/2/2015Robert A BreyerDirectorSell5,000$72.91$364,550.00View SEC Filing  
1/26/2015Gordon G PughCOOSell15,000$70.02$1,050,300.00View SEC Filing  
1/23/2015Shane CookeInsiderSell118,000$69.13$8,157,340.00View SEC Filing  
1/16/2015Floyd E BloomDirectorSell20,000$67.12$1,342,400.00View SEC Filing  
1/15/2015Elliot EhrichCMOSell18,375$66.45$1,221,018.75View SEC Filing  
1/15/2015James M FratesCFOSell10,000$66.86$668,600.00View SEC Filing  
1/7/2015Kathryn L BibersteinSVPSell28,374$65.00$1,844,310.00View SEC Filing  
1/2/2015Robert A BreyerDirectorSell5,000$58.57$292,850.00View SEC Filing  
12/11/2014Richard F PopsCEOSell100,000$56.04$5,604,000.00View SEC Filing  
12/10/2014James M FratesCFOSell18,870$56.07$1,058,040.90View SEC Filing  
12/9/2014Michael J LandineSVPSell18,000$56.82$1,022,760.00View SEC Filing  
12/5/2014Kathryn L BibersteinSVPSell15,433$57.61$889,095.13View SEC Filing  
12/1/2014Robert A BreyerDirectorSell5,000$54.64$273,200.00View SEC Filing  
11/19/2014James M FratesCFOSell8,000$53.86$430,880.00View SEC Filing  
11/13/2014Richard F PopsCEOSell100,000$52.87$5,287,000.00View SEC Filing  
11/7/2014James M FratesCFOSell13,303$49.98$664,883.94View SEC Filing  
11/6/2014Kathryn L BibersteinSVPSell20,000$50.54$1,010,800.00View SEC Filing  
11/3/2014Robert A BreyerDirectorSell5,000$50.05$250,250.00View SEC Filing  
10/23/2014Gordon G PughCOOSell14,577$45.00$655,965.00View SEC Filing  
10/8/2014James M FratesCFOSell16,000$41.00$656,000.00View SEC Filing  
10/1/2014Robert A BreyerDirectorSell5,000$42.59$212,950.00View SEC Filing  
9/24/2014James M FratesCFOSell16,000$45.29$724,640.00View SEC Filing  
9/18/2014Michael J LandineSVPSell15,000$45.60$684,000.00View SEC Filing  
9/17/2014Gordon G PughCOOSell14,900$45.04$671,096.00View SEC Filing  
9/17/2014Richard F PopsCEOSell50,000$44.89$2,244,500.00View SEC Filing  
9/10/2014James M FratesCFOSell16,000$43.18$690,880.00View SEC Filing  
9/2/2014Gordon G PughCOOSell1,100$45.08$49,588.00View SEC Filing  
9/2/2014Robert A BreyerDirectorSell5,000$45.12$225,600.00View SEC Filing  
8/27/2014James M FratesCFOSell16,000$45.08$721,280.00View SEC Filing  
8/26/2014Gordon G PughCOOSell16,000$45.00$720,000.00View SEC Filing  
8/13/2014James M FratesCFOSell15,000$41.37$620,550.00View SEC Filing  
8/11/2014Elliot EhrichCMOSell16,667$41.65$694,180.55View SEC Filing  
8/4/2014Gordon G PughCOOSell23,250$43.20$1,004,400.00View SEC Filing  
8/1/2014Robert A BreyerDirectorSell5,000$42.53$212,650.00View SEC Filing  
7/16/2014James M FratesCFOSell8,000$46.50$372,000.00View SEC Filing  
7/9/2014Elliot EhrichCMOSell16,667$47.41$790,182.47View SEC Filing  
7/9/2014James M FratesCFOSell7,000$47.41$331,870.00View SEC Filing  
7/3/2014Michael J LandineSVPSell7,000$51.31$359,170.00View SEC Filing  
7/2/2014Richard F PopsCEOSell50,000$51.69$2,584,500.00View SEC Filing  
7/1/2014Gordon G PughCOOSell16,000$46.49$743,840.00View SEC Filing  
7/1/2014Robert A BreyerDirectorSell5,000$50.57$252,850.00View SEC Filing  
6/26/2014Michael J LandineSVPSell10,000$49.92$499,200.00View SEC Filing  
6/25/2014James M FratesCFOSell7,000$50.22$351,540.00View SEC Filing  
6/25/2014Richard F PopsCEOSell50,000$49.87$2,493,500.00View SEC Filing  
6/20/2014Paul J MitchellDirectorSell17,000$50.00$850,000.00View SEC Filing  
6/19/2014Elliot EhrichCMOSell17,282$47.10$813,982.20View SEC Filing  
6/19/2014Michael J LandineSVPSell10,000$47.01$470,100.00View SEC Filing  
6/18/2014Richard F PopsCEOSell50,000$46.72$2,336,000.00View SEC Filing  
6/17/2014Kathryn L BibersteinSVPSell8,400$47.41$398,244.00View SEC Filing  
6/11/2014James M FratesCFOSell7,000$47.72$334,040.00View SEC Filing  
6/9/2014Elliot EhrichCMOSell16,667$48.15$802,516.05View SEC Filing  
6/2/2014Gordon G PughCOOSell16,000$45.34$725,440.00View SEC Filing  
6/2/2014Robert A BreyerDirectorSell5,000$45.18$225,900.00View SEC Filing  
5/30/2014Rebecca PetersonSVPSell21,981$45.86$1,008,048.66View SEC Filing  
5/23/2014Rebecca PetersonSVPSell1,321$45.08$59,550.68View SEC Filing  
5/22/2014Elliot EhrichCMOSell2,378$44.49$105,797.22View SEC Filing  
5/22/2014Gordon PughCOOSell15,700$45.25$710,425.00View SEC Filing  
5/22/2014Rebecca PetersonSVPSell19,807$44.02$871,904.14View SEC Filing  
5/21/2014Elliot EhrichCMOSell1,981$44.00$87,164.00View SEC Filing  
5/21/2014James FratesCFOSell7,000$44.30$310,100.00View SEC Filing  
5/20/2014Rebecca PetersonSVPSell20,307$44.05$894,523.35View SEC Filing  
5/19/2014Elliot EhrichCMOSell2,206$43.55$96,071.30View SEC Filing  
5/8/2014Floyd BloomDirectorSell10,000$46.16$461,600.00View SEC Filing  
5/5/2014Robert BreyerDirectorSell5,000$46.72$233,600.00View SEC Filing  
5/1/2014Paul MitchellDirectorSell1,000$45.90$45,900.00View SEC Filing  
4/9/2014James FratesCFOSell7,000$42.91$300,370.00View SEC Filing  
4/1/2014Paul MitchellDirectorSell1,500$44.14$66,210.00View SEC Filing  
3/19/2014James FratesCFOSell7,000$46.84$327,880.00View SEC Filing  
3/11/2014Wendy DixonDirectorBuy1,600$47.37$75,792.00View SEC Filing  
3/5/2014James FratesCFOSell7,000$47.78$334,460.00View SEC Filing  
2/18/2014Elliot EhrichCMOSell7,718$52.45$404,809.10View SEC Filing  
2/3/2014Paul MitchellDirectorSell1,500$48.15$72,225.00View SEC Filing  
1/21/2014Elliot EhrichCMOSell7,718$48.61$375,171.98View SEC Filing  
1/16/2014Elliot EhrichCMOSell14,555$47.35$689,179.25View SEC Filing  
1/16/2014Gordon PughCOOSell30,000$47.16$1,414,800.00View SEC Filing  
1/16/2014James FratesCFOSell7,000$47.40$331,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Alkermes PLC (NASDAQ:ALKS)
DateHeadline
capitalcube.com logoETF’s with exposure to Alkermes Plc : August 25, 2016 (NASDAQ:ALKS)
www.capitalcube.com - August 25 at 3:28 PM
capitalcube.com logoAlkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : August 24, 2016 (NASDAQ:ALKS)
www.capitalcube.com - August 24 at 11:43 AM
investornewswire.com logoAlkermes plc (NASDAQ:ALKS) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:ALKS)
www.investornewswire.com - August 23 at 3:26 PM
investornewswire.com logoCan Alkermes plc (NASDAQ:ALKS) Keep Up With Analyst Expectations? - Investor Newswire (NASDAQ:ALKS)
www.investornewswire.com - August 20 at 3:29 PM
benzinga.com logo11 Biopharma CEOs To Follow On Twitter (NASDAQ:ALKS)
www.benzinga.com - August 18 at 11:49 AM
investornewswire.com logoWill Alkermes plc (NASDAQ:ALKS) Hit $66 Price Target? - Investor Newswire (NASDAQ:ALKS)
www.investornewswire.com - August 16 at 3:27 PM
thestreet.com logoWant a Dash for Trash? Why Not Look at Alkermes (NASDAQ:ALKS)
realmoney.thestreet.com - August 15 at 10:41 AM
stocksdaily.net logoAlkermes plc (NASDAQ:ALKS) Ratings in Focus - Stocks Daily (NASDAQ:ALKS)
www.stocksdaily.net - August 13 at 3:25 PM
stocksdaily.net logoAlkermes plc (NASDAQ:ALKS) Ratings in Focus (NASDAQ:ALKS)
www.stocksdaily.net - August 13 at 11:36 AM
fidaily.com logoAlkermes plc (ALKS) Holdings Increased by Canada Pension Plan Investment Board - Finance Daily (NASDAQ:ALKS)
www.fidaily.com - August 11 at 3:28 PM
capitalcube.com logoAlkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : August 11, 2016 (NASDAQ:ALKS)
www.capitalcube.com - August 11 at 12:40 PM
ftsenews.co.uk logoNew Broker Ratings For Alkermes Plc (NASDAQ:ALKS) - FTSE ... - FTSE News (NASDAQ:ALKS)
www.ftsenews.co.uk - August 9 at 12:11 PM
streetupdates.com logoInvestors Spotlight: Stereotaxis, Inc. (NASDAQ:STXS) , Alkermes plc (NASDAQ:ALKS) - Street Updates (NASDAQ:ALKS)
www.streetupdates.com - August 9 at 12:11 PM
tradecalls.org logoJefferies Maintains Alkermes Plc to Buy with Price Target $62.00 - Trade Calls (NASDAQ:ALKS)
www.tradecalls.org - August 8 at 8:13 AM
tradecalls.org logoAlkermes plc (ALKS) Shares are Down -2.63% – Trade Calls - Trade Calls (NASDAQ:ALKS)
www.tradecalls.org - August 8 at 8:13 AM
streetinsider.com logoAlkermes plc (ALKS) Submits ARISTADA sNDA for Schizophrenia; Receives USPTO Notice of Allowance on Related ... - StreetInsider.com (NASDAQ:ALKS)
www.streetinsider.com - August 8 at 8:13 AM
finance.yahoo.com logo7:01 am Alkermes submits a sNDA to the FDA for a two-month dosing interval of ARISTADA extended-release injectable suspension for the treatment of schizophrenia; also announces USPTO issued a NOA for ARISTADA (NASDAQ:ALKS)
finance.yahoo.com - August 8 at 8:13 AM
publicnow.com logoAlkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia (NASDAQ:ALKS)
www.publicnow.com - August 8 at 8:13 AM
capitalcube.com logoETF’s with exposure to Alkermes Plc : August 4, 2016 (NASDAQ:ALKS)
www.capitalcube.com - August 4 at 3:28 PM
capitalcube.com logoAlkermes Plc :ALKS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016 (NASDAQ:ALKS)
www.capitalcube.com - August 3 at 3:30 PM
finance.yahoo.com logoALKERMES PLC. Financials (NASDAQ:ALKS)
finance.yahoo.com - August 3 at 3:30 PM
live-pr.com logoNew Market Research Report: Alkermes Plc (ALKS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile (NASDAQ:ALKS)
www.live-pr.com - August 1 at 3:26 PM
News IconComprehensive Report on: Alkermes plc (NASDAQ:ALKS), MEDNAX, Inc. (NYSE:MD) - News Oracle (NASDAQ:ALKS)
www.newsoracle.com - July 29 at 3:26 PM
zacks.com logoAlkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook (NASDAQ:ALKS)
www.zacks.com - July 29 at 10:49 AM
seekingalpha.com logoAlkermes Plc (ALKS) Richard Pops on Q2 2016 Results - Earnings Call Transcript (NASDAQ:ALKS)
seekingalpha.com - July 28 at 4:27 PM
rttnews.com logoEARNINGS SUMMARY: Details of Alkermes plc Q2 Earnings Report (NASDAQ:ALKS)
www.rttnews.com - July 28 at 12:05 PM
streetinsider.com logoAlkermes plc (ALKS) Tops Q2 EPS by 9c (NASDAQ:ALKS)
www.streetinsider.com - July 28 at 12:05 PM
biz.yahoo.com logoAlkermes Plc Earnings Call scheduled for 8:30 am ET today (NASDAQ:ALKS)
biz.yahoo.com - July 28 at 8:30 AM
sg.finance.yahoo.com logoAlkermes reports 2Q loss (NASDAQ:ALKS)
sg.finance.yahoo.com - July 28 at 8:20 AM
insidermonkey.com logoA Look At Recro Pharma Inc (REPH) and Alkermes Plc (ALKS)’s Topline Triumph (NASDAQ:ALKS)
www.insidermonkey.com - July 27 at 3:00 PM
reuters.com logoRecro Pharma's intravenous painkiller succeeds in trial, shares soar (NASDAQ:ALKS)
www.reuters.com - July 26 at 9:27 PM
nasdaq.com logoAlkermes (ALKS) Shares Cross Above 200 DMA (NASDAQ:ALKS)
www.nasdaq.com - July 26 at 9:27 PM
investornewswire.com logoCan Shares Of Alkermes plc (NASDAQ:ALKS) Hit $77? - Investor Newswire (NASDAQ:ALKS)
www.investornewswire.com - July 26 at 3:25 PM
fidaily.com logoCowen & Company Upgrades Rating On Alkermes plc (ALKS) To "Market Perform" - Finance Daily (NASDAQ:ALKS)
www.fidaily.com - July 26 at 12:58 PM
News IconStock Focus: Following Analyst Expectations on Shares of Alkermes plc (NASDAQ:ALKS) - Engelwood Daily (NASDAQ:ALKS)
www.engelwooddaily.com - July 23 at 3:25 PM
News IconAlkermes plc (NASDAQ:ALKS) Upcoming Earnings: What matter for investors? - The Voice Registrar (NASDAQ:ALKS)
voiceregistrar.com - July 23 at 7:52 AM
marketrealist.com logoWhat’s Been Beating down the Fidelity Growth Company Fund in 2016? (NASDAQ:ALKS)
marketrealist.com - July 22 at 7:53 PM
finance.yahoo.com logoAlkermes to Host Conference Call to Discuss Second Quarter 2016 Financial Results (NASDAQ:ALKS)
finance.yahoo.com - July 21 at 4:00 PM
News IconAlkermes plc (NASDAQ:ALKS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ALKS)
www.engelwooddaily.com - July 21 at 3:26 PM
tradecalls.org logoBarclays Maintains Alkermes Plc to Overweight with Price Target $65.00 - Trade Calls (NASDAQ:ALKS)
www.tradecalls.org - July 21 at 3:26 PM
News IconAlkermes Plc Ord (NASDAQ:ALKS) Sellers Covered 12.81% of Their Shorts - Consumer Eagle (NASDAQ:ALKS)
www.consumereagle.com - July 19 at 3:25 PM
investornewswire.com logoIs $77 Price Target Attainable For Alkermes plc (NASDAQ:ALKS)? - Investor Newswire (NASDAQ:ALKS)
www.investornewswire.com - July 19 at 3:25 PM
tradecalls.org logoShares of Alkermes plc (ALKS) Drops by -2.8% - Trade Calls (NASDAQ:ALKS)
www.tradecalls.org - July 18 at 3:28 PM
News IconTrading Performance and Target Watch for Alkermes plc (NASDAQ:ALKS) - Press Telegraph (NASDAQ:ALKS)
presstelegraph.com - July 18 at 8:14 AM
News IconHow Many Alkermes Plc (NASDAQ:ALKS)'s Analysts Are Bearish? - Press Telegraph (NASDAQ:ALKS)
presstelegraph.com - July 16 at 3:25 PM
news.cmlviz.com logoAlkermes plc Realized Volatility Hits Extreme Level - CML News (NASDAQ:ALKS)
news.cmlviz.com - July 14 at 3:28 PM
investornewswire.com logoStrong Sell Calls For Alkermes plc (NASDAQ:ALKS) At 1 - Investor Newswire (NASDAQ:ALKS)
www.investornewswire.com - July 13 at 3:28 PM
streetupdates.com logoReview of Analysts Ranking: Galena Biopharma, Inc. (NASDAQ:GALE) , Alkermes plc (NASDAQ:ALKS) - Street Updates (NASDAQ:ALKS)
www.streetupdates.com - July 13 at 3:28 PM
nasdaq.com logoSPDR S&P Biotech ETF Experiences Big Inflow (NASDAQ:ALKS)
www.nasdaq.com - July 12 at 8:56 PM
streetupdates.com logoTwo Stocks to Watch: Alkermes plc (NASDAQ:ALKS) , Escalon Medical Corp. (NASDAQ:ESMC) - Street Updates (NASDAQ:ALKS)
www.streetupdates.com - July 12 at 3:30 PM

Social

Alkermes PLC (NASDAQ:ALKS) Chart for Saturday, August, 27, 2016


Last Updated on 8/27/2016 by MarketBeat.com Staff